CONDENSED HETEROCYCLIC COMPOUNDS,申请号RU20070143966-传众专利搜索

CONDENSED HETEROCYCLIC COMPOUNDS

申请公布号：RU2408586(C2)

申请号：RU20070143966

申请日期：2006.04.26

申请公布日期：2011.01.10

申请人：

TAKEDA FARMAS'JUTIKAL KOMPANI LIMITED

发明人：ASO KAZUJOSI;MOTIZUKI MITIJO;G'JORKOS AL'BERT CHARL'Z;KORRETT KRISTOFER PITER;CHO SUK JANG;PRATT SKOTT ALAN;SIDEM KRISTOFER STEFEN

分类号：A61K31/4184;A61K31/4188;A61P25/00;C07D235/04;C07D235/24;C07D235/26;C07D235/30;C07D401/04;C07D401/10;C07D401/12;C07D403/04;C07D403/10;C07D405/10;C07D409/10;C07D413/10;C07D471/04

主分类号：A61K31/4184

摘要：FIELD: chemistry. ^ SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof, having CRP receptor antagonist activity. In formula (I) R1 denotes C3-C8 alkyl, optionally substituted with hydroxyl; phenyl optionally substituted with 1-3 substitutes selected from halogen, nitro, amino, hydroxyl, C1-C4 alkoxy, C1-C4 alkyl, optionally substituted with hydroxyl or C1-C4 alkylamino; naphthyl; C-bonded 5-6-member heteroaryl with 1-2 heteroatoms selected from S, N or O, optionally substituted with C1-C4 alkyl, C1-C4 alkoxy or acetyl; N-bonded 5-member heteroaryl with 1-2 heteroatoms selected from N, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl or phenyl; R2 denotes phenyl, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl, halogenC1-C4alkyl, C1-C4 alkoxy, halogenC1-C4alkoxy, halogen, hydroxy, di(C1-C4 alkyl)amino or di(C1-C4 alkyl)aminocarbonyl; or a heterocyclic group which is pyridyl, optionally substituted with 1-3 substitutes selected from C1-C4 alkyl, C1-C4 alkoxy or di(C1-C4 alkyl)amino; X denotes -NR3-, where R3 denotes C1-C4 alkyl, optionally substituted with hydroxyl, carboxyl or C1-C4 alkoxycarbonyl; Y1 denotes CR3a, where R3a denotes hydrogen, halogen, cyano, hydroxy, C1-C4 alkyl, optionally substituted with hydroxyl or halogen, C1-C4 alkoxy optionally substituted with halogen; Y2 denotes CR3b, where R3b denotes hydrogen or halogen; Y3 denotes N or CR3c, where R3c denotes hydrogen; and Z denotes O or -NR4-, where R4 denotes hydrogen. ^ EFFECT: invention also pertains to a method of producing compounds of formula (I), a pharmaceutical composition, an inhibiting method, CRF receptor antagonists and use thereof to prepare a medicinal agent. ^ 25 cl, 9 tbl, 163 ex